Abstract
Aim: This non-interventional observational study aimed to describe the clinical outcomes of patients with T2DM treated with Gla-300 during the period of Ramadan.
Background: Type 2 diabetes mellitus (T2DM) patients who decide to fast during the holy month of Ramadan face several challenges in achieving glycemic control without increasing the risk of hypoglycemia. Insulin glargine-300 (Gla-300) has well-established safety and efficacy in improving glycemic control in multiple randomized clinical trials (RCTs). However, limited evidence is available regarding its safety and effectiveness during fasting.
Objective: The objective of this study was to assess the safety and clinical outcomes of insulin glargine-300 (Gla-300) in T2DM patients before, during, and after Ramadan.
Methods: We conducted a prospective, observational, non-comparative, multicenter study on patients with T2DM currently treated with Gla-300 who planned to fast and continue on Gla-300 during Ramadan in four countries (Egypt, Jordan, Lebanon, and Turkey). The study outcomes included the change in glycemic parameters and incidence of hypoglycemia before, during, and after Ramadan.
Results: One hundred and forty T2DM patients were included. Nearly 61% of the included patients had a duration of diabetes of <10 years. The mean Gla-300 daily doses during the pre-Ramadan, Ramadan, and post-Ramadan periods were 22.2 ±7.4, 20.4 ±7.5, and 22.5 ±4.7 IU, respectively. The mean change values from pre-Ramadan to Ramadan and post-Ramadan were -1.7 ±6.9 IU and 0.5 ±4.7 IU, respectively, among the included patients. The mean HbA1c decreased during the study period initiating from 7.9% ±1.4% pre-Ramadan to 6.9% ±0.4% post-Ramadan. The overall HBA1c target value was 6.9% ±0.4%, while the HbA1c target was achieved by 29 patients (21.9%). The mean fasting blood glucose (FPG) showed a reduction from baseline value in the post-Ramadan period by -0.9 ±2.3 mmol/L. Five patients (3.57%) had symptomatic documented hypoglycemia during Ramadan, and none was considered to have severe hypoglycemia.
Conclusion: Our study showed that insulin Gla-300 maintained the glycemic control of T2DM patients who decided to fast during the holy month of Ramadan without increasing the risk of hypoglycemia. Regular self-monitoring of blood glucose levels during Ramadan is highly recommended to avoid possible complications.
Keywords: type-2 diabetes mellitus, insulin, glargine, ramadan, randomized clinical trials.
[http://dx.doi.org/10.1016/j.diabres.2020.108593] [PMID: 33316310]
[http://dx.doi.org/10.1007/s13300-020-00886-y] [PMID: 32909192]
[http://dx.doi.org/10.1016/j.diabres.2019.02.027] [PMID: 30836132]
[http://dx.doi.org/10.1152/ajpendo.2001.280.1.E50]
[http://dx.doi.org/10.1016/S0003-4266(06)72541-0]
[PMID: 11806014]
[http://dx.doi.org/10.1038/sj.ejcn.1601047] [PMID: 10878654]
[http://dx.doi.org/10.22037/ijpr.2019.1100842] [PMID: 32184879]
[http://dx.doi.org/10.1136/bmj.307.6899.292] [PMID: 8374375]
[http://dx.doi.org/10.1016/j.dsx.2021.102323]
[http://dx.doi.org/10.1016/j.diabres.2020.108154] [PMID: 32330510]
[http://dx.doi.org/10.2337/dc10-0896] [PMID: 20668157]
[http://dx.doi.org/10.2337/diacare.26.11.3080] [PMID: 14578243]
[http://dx.doi.org/10.7326/0003-4819-138-12-200306170-00006]
[http://dx.doi.org/10.1016/j.diabres.2020.108189] [PMID: 32360709]
[http://dx.doi.org/10.1016/j.diabres.2017.03.003] [PMID: 28347497]
[http://dx.doi.org/10.1016/j.diabres.2006.05.012] [PMID: 16815586]
[http://dx.doi.org/10.1007/s00592-008-0062-7] [PMID: 18825302]
[http://dx.doi.org/10.1111/dme.12685] [PMID: 25581456]
[http://dx.doi.org/10.1016/j.diabres.2019.03.031] [PMID: 30946851]
[http://dx.doi.org/10.1111/dom.12438] [PMID: 25641260]
[http://dx.doi.org/10.2337/dc18-0559]
[http://dx.doi.org/10.1136/bmjdrc-2020-001248]